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Background: Idiopathic REM sleep behaviour disorder (iRBD) has been recognised as a signiﬁcant
biomarker for developing a neurodegenerative alpha-synucleinopathy, which is why iRBD is considered
to be a prodromal state for alpha-synucleinopathies including Parkinson's disease (PD). Many patients
with PD suffer from complaints of pain and present impaired somatosensory function. We hypothesized
that pain perception and somatosensory function could be altered already in a preclinical stage of PD
including iRBD. Hence, the objective of this study was to investigate pain perception and somatosensory
function in patients with iRBD.
Methods: Quantitative sensory testing (QST), laser evoked potentials (LEPs), and conditioned pain
modulation (CPM) testing were performed in 13 iRBD patients without any clinical signs of PD or nar-
colepsy (11 males, 2 females, mean age 65.2 years) and 15 gender- and age-matched healthy control
subjects (12 males, 3 females, mean age 65.8 years).
Results: Thermal detection thresholds were higher in the iRBD group compared with the control group
(cold detection threshold (CDT) p ¼ 0.020, thermal sensory limen (TSL) p ¼ 0.001), indicating an
impaired temperature sensation in iRBD patients. The N2/P2 LEPs amplitude was smaller in iRBD patients
than controls, but not statistically signiﬁcant (p ¼ 0.053).
Conclusions: This study found an impaired somatosensory function in iRBD patients, suggesting that
somatosensory impairment might be an early feature in the neurodegenerative process of PD.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
REM sleep behaviour disorder (RBD) is characterized by loss of
muscle atonia during rapid eye movement (REM) sleep (REM sleep
without atonia, RSWA) documented by polysomnography (PSG)
and presence of dream enactment (vocalizations and/or complex
motor behaviour) [1,2]. Idiopathic RBD (iRBD) is an important
predictor of neurodegenerative alpha-synucleinopathies including
Parkinson's disease (PD), Lewy body dementia, andmultiple system
atrophy. Early reports have suggested that up to 80% of the iRBD
patients develop a neurodegenerative disease [3e5]. RBD may be.V. Strobel).
B.V. This is an open access article ucaused by involvement of the subcoeruleus nucleus and related
structures thereby interfering with active REM inhibition of spinal
motor neurons [6]. Thus, RBD may represent an early stage of an
incipient synucleinopathy due to a dissemination of the alpha-
synuclein pathology, starting in the medulla oblongata, pontine
tegmentum, and olfactory bulb/anterior olfactory nucleus and then
ascending to the mesencephalon, including substantia nigra and at
last to the neocortex [7].
Patients with PD have preclinical symptoms for several years
before the motor symptoms appear. The current treatment options
for PD using dopaminergic drugs modify the symptoms, however
they have no inﬂuence on the prognosis. Currently, no proven
therapy modiﬁes the neurodegenerative process when PD is clini-
cally obvious. Preclinical diagnosis of PD would imply a potential
for future neuroprotective agents. When PD is diagnosed, ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
CDT cold detection threshold
CPM conditioned pain modulation
CPT cold pain threshold
DFNS The German Research Network on Neuropathic Pain
HPT heat pain threshold
IENFD intraepidermal nerve ﬁbre density
iRBD idiopathic rapid eye movement sleep behaviour
disorder
KSS Karolinska Sleepiness Scale
LEPs laser evoked potentials
MDI Major Depression Inventory
MDT mechanical detection threshold
MMSE Mini-Mental State Examination
MPT mechanical pain threshold
NRS numerical rating scale
PD Parkinson's disease
PPT pressure pain threshold
PSQI Pittsburgh Sleep Quality Index
QST quantitative sensory testing
RBD rapid eye movement sleep behaviour disorder
SFN small ﬁbre neuropathy
SIT-12 Snifﬁn’ Sticks 12-identiﬁcation test
TSL thermal sensory limen
UPDRS-III the motor part of the Uniﬁed Parkinson's Disease
Rating Scale
VDT vibration detection threshold
WDT warm detection threshold
WUR wind-up ratio
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of the brain stem including substantia nigra is apparent. Why any
potential protective therapy should be presented years prior to
onset of motor symptoms when the neural involvement is less
certain. Therefore, early prodromalmarkers for PD are central. IRBD
has the potential to provide a preclinical marker for alpha-
synucleinopathy. Studies have found some other potential
markers for incipient neurodegenerative synucleinopathy in pa-
tients with iRBDefor instance, as in PD, patients with iRBD have
impaired olfaction [8e10] and autonomic disturbances [11].
Many patients with PD suffer from pain [12,13]. Studies in pa-
tients with PD have shown somatosensory abnormalities when
examined with quantitative sensory testing (QST) [14]. PD patients
present increased cold and warm detection thresholds compared
with healthy control subjects, indicating that temperature sensa-
tion could be impaired in PD patients [15,16]. Studies examining
cold and heat pain thresholds in PD patients are inconsistent;
increased, decreased, and unaltered thresholds have been found
[15e18]. A study with laser evoked potentials (LEPs) has found that
patients with PD have lower N2/P2 amplitudes than healthy con-
trols [19]. LEPs are the easiest and most reliable of the neuro-
physiological methods for assessing the function of nociceptive
pathways [20]. It is unclear which parts of the nervous system and
whichmechanisms that are involved in PD patients’ somatosensory
deﬁcits. One possible mechanism is that the dopaminergic dener-
vation may lead to a loss of response speciﬁcity, resulting in
transmission of less-differentiated and noisier information to
cortical regions, thus causing increased thresholds [14]. Another
potential mechanism is the degeneration of peripheral nerve
endings. Moreover, a study analysing skin biopsies in patients with
PD observed a reduced number of free and encapsulated nerve
endings [16]. This suggests that a small ﬁbre neuropathy could
explain, at least in part, the sensory impairment in PD.
Theoretically, a degenerative process in the brainstem could affect
the descending pain inhibitory system, which can be experimen-
tally measured with conditioned pain modulation (CPM)
testing [21].
Furthermore, somatosensory function and pain perception
could hypothetically be already changed in a preclinical stage of PD.
Therefore, the objective of this study was to examine somatosen-
sory function and pain perception, measured with QST, LEPs, and
CPM, in patients with iRBD. If iRBD patients have an altered pain
perception and sensory function compared with healthy control
subjects, these parameters could be studied as potential prodromal
diagnostic markers for later neurodegenerative disease. In addition,
new knowledge about changed pain perception and sensoryfunction in iRBD patients would contribute to a better pathophys-
iological understanding of pain and sensory impairment in PD.
2. Materials and methods
2.1. Subjects
Patients with a clinical diagnosis of iRBD were recruited from
the Department of Neurology and Department of Clinical Neuro-
physiology, Aarhus University Hospital, the Department of
Neurology, Viborg Regional Hospital, and Danish Center of Sleep
Medicine, Glostrup Hospital, Denmark, between November 2015
and August 2016. The inclusion criteria were age between 40 and
80 years, history of dream-enacting behaviour, and REM sleep
without atonia veriﬁed with video polysomnography in accordance
to American Academy of Sleep Medicine [2]. Exclusion criteria, in
both the patient and control group, were symptoms of Parkinson's
disease (rigidity, rest tremor, bradykinesia, postural instability), any
signs indicating peripheral neuropathy or a history of diabetes
mellitus or alcoholism, severe psychiatric disorders, severe disease
(cancer, cardiac/lung/renal insufﬁciency), narcolepsy, chronic pain
(> 3 on the numerical rating scale (NRS), 0 ¼ no pain, 10 ¼ worst
pain imaginable), and cognitive impairment (Mini-Mental State
Examination (MMSE), cut-off score: <25).
Healthy sex- and age-matched subjects without a history of
dream-enacting behaviour served as control group. By clinical
history there was no evidence that the controls had RBD. All sub-
jects gave their written informed consent prior to participation in
the study. The study was approved by the Central Denmark Region
Committees on Health Research Ethics (reference number: 1-10-
72-180-15).
2.2. Sleep and neurological assessment
The day before the examination day, subjects completed two
questionnaires: The Pittsburgh Sleep Quality Index (PSQI), which
assesses sleep quality the preceding month, and the Major
Depression Inventory (MDI). Immediately before the QST, the
subjects rated their subjective level of sleepiness using the Kar-
olinska Sleepiness Scale (KSS).
Neurological examination including the motor examination part
of the Uniﬁed Parkinson's Disease Rating Scale from the Interna-
tional Parkinson and Movement Disorder Society (MDS-UPDRS
Part III) was performed in both groups to ensure that the subjects
did not have peripheral neuropathy or Parkinson's disease.
The subjects' olfactory sense was examined with Snifﬁn’ Sticks
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sented, and then the subjects had to identify them by selecting from
a list of four descriptors. Analgesics and pain, if any, were registered
with pain localisation and rating of intensity (NRS 0e10).
2.3. Quantitative sensory testing
QST assesses and quantiﬁes different nociceptive and non-
nociceptive modalities of the somatosensory nervous system.
Before testing, the subjects’ reaction time was examined, as the
reaction time may have an inﬂuence on thermal thresholds. The
subjects let go of a button as soon as possible after the investigator
activated a loud sound and a red light, and the reaction time was
given in milliseconds. The averaged reaction time of three
consecutive measurements was then calculated.
Testing was performed on the dorsum of the dominant hand
using the QST protocol of the German Research Network on
Neuropathic Pain (DFNS) [22]. The tests for vibration and thermal
thresholds were also conducted on the dorsum of the dominant
foot. The same investigator (AVS) conducted all the tests, which
were always performed in the following order: cold detection
threshold (CDT), warm detection threshold (WDT), thermal sensory
limen (TSL), cold pain threshold (CPT), heat pain threshold (HPT),
mechanical detection threshold (MDT), mechanical pain threshold
(MPT), wind-up ratio (WUR), vibration detection threshold (VDT),
and pressure pain threshold (PPT).
Standardised instructions to the subjects were used. Before
testing in the test area, a demonstration of each test was performed
at a practice area to ensure that the subjects were familiar with the
testing procedure.
2.4. Laser evoked potentials
LEPs assess the function of nociceptive pathways. Cutaneous
stimuli were delivered by a Nd:YAP laser (Neodimium:Yttrium-
Aluminium-Perovskite; 1.34 mm wavelength, beam diameter
6 mm, 11 ms pulse duration (Stimul 1340, Electronic Engineering,
Florence, Italy)) on the dorsum of the dominant hand. A red
helium-neon laser confocal with the infrared beam visually indi-
cated the irradiated area.
The subjects were asked to rate the pain after each stimulation
using the NRS (0e10). The stimuli (a pinprick) elicited a moder-
ately painful sensation; usually with a NRS score of 4e6. The
energy intensities ranged from 13.26 to 18.57 J/cm2. After each
stimulus, the laser beam stimulation location was slightly shifted
in a random direction to avoid skin damage and sensitization or
fatigue of the nociceptors [23]. The interstimulus interval ranged
from 20 to 30 s.
The subjects lay on a bed in a warm and silent room. They wore
protective googles and were instructed to keep their eyes open and
focus their attention on a spot on the wall and relax their facial
muscles when the laser stimulation took place.
Laser evoked potentials were obtained using four surface
recording electrodes placed over Cz, the temporal region contra-
lateral to the stimulation site (T3 or T4), the frontoparietal region
ipsilateral to the stimulation site (Fp1 or Fp2), and nasion. The N2
and P2 potentials were recorded by the Cz referred to the nasion
electrode. Potential ocular artefacts were detected with an elec-
trode located on the lower orbicularis oculi muscle and referred to
an electrode on the cheek (electrooculogram). The software pro-
gramme Keypoint.NET (Dantec, Skovlunde, Denmark) was used for
the recordings.
Latencies of N2 and P2 and amplitudes of the N2/P2 complex
were averaged from 15 artefact-free recordings. The analyses were
done off-line. All examinations were ﬁrst anonymized by theexaminer (AVS), and then cursors were set in consensus by two
specialists in clinical neurophysiology (MOT and HT), who were
blinded about whether the recordings were from patients or
healthy controls.
2.5. Conditioned pain modulation testing
CPM testing investigates the endogenous pain inhibitory pathway
based on the “pain inhibits pain” phenomenon. The test stimulus is
the term for the painful stimulus uponwhich the conditioning effect
is tested.Mechanical pressure andheatwere used as test stimuli [24].
Pressure pain threshold (PPT)wasmeasured using amanual pressure
algometer (Bridge ampliﬁer, Somedic AB, Sweden) with a contact
area of 1 cm2. The testingwas performed above the transverse part of
the dominant trapezius muscle. During the pressure stimulation,
subjects should press a button as soon as the pressure sensation
became painful (PPT) whereby the pressure value was frozen on a
digital display. The subjects were familiarised with the testing pro-
cedurewith a demonstration on the non-dominant trapeziusmuscle.
PPT was measured three times and a mean PPT was calculated. Heat
pain threshold (HPT) was measured using a Thermal Sensory Ana-
lyser (TSA 2001-II, Medoc, Israel). The testing was done at the
dominant volar forearm. The subjects were instructed to push a
button as soon as the heat sensation became painful. HPT was
measured three times and a mean HPT was calculated.
The conditioning stimulus is the term for the stimulus used to
induce the change in pain perception. The conditioning stimulus
was an ice water immersion (between 1 and 1 C) of the non-
dominant hand to wrist level. The subjects were instructed to
keep the hand in the water for one minute or until the pain became
unbearable. The duration of the water immersion was registered.
Immediately after the withdrawal of the hand from the ice
water, PPT was measured on the dominant trapezius muscle using
the same procedure as previously described. One minute after
withdrawal of the hand, HPT was measured on the dominant volar
forearm. Finally, PPT was measured two and three minutes after
the end of the ice water immersion.
Conditioned pain modulation (CPM) is the term for the phe-
nomenon through which the conditioning stimulus affects
perception of the test stimuli. The calculation of the CPM response
was conducted by subtracting the second test stimuli PPT and HPT
from the ﬁrst test stimuli PPT and HPT, thus the pain inhibitionwas
denoted with a negative value [24].
After the CPM testing, subjects were asked to rate the maximum
pain intensity and pain unpleasantness during the ice water bath
on the NRS 0e10).
2.6. Statistical analysis
Statistical comparisons of continuous data between groups
were performed using unpaired two-sample t-test (normal distri-
bution) or ManneWhitney U test (non-normal distribution) after
testing for normal distribution using QeQ plots. Categorical data
were tested using Fisher's exact test. p-values below 0.05 were
considered statistically signiﬁcant. Statistical analysis was con-
ducted using Stata version 13.2.
The rawQST datawere via the programme eQuiSTA transformed
into z-values based on a reference database of healthy controls,
thus normalising for age, gender, and body location of testing [22].
The resulting z-scores are independent of the original units of
measurements and are therefore useful for the creation of so-
matosensory proﬁles. The 95% conﬁdence interval of z-values of
reference controls is between1.96 andþ1.96. Z-scores above zero
indicate hyperfunction (gain of function), which means that the
subjects are more sensitive to the tested parameter than reference
QST parameter
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Fig. 1. Somatosensory proﬁles of the dorsal hand based on quantitative sensory testing
(QST) in patients with idiopathic REM sleep behaviour disorder and healthy control
subjects. Mean z-scores ± standard error of the mean. For further explanation, see the
Statistical analysis section. CDT: cold detection threshold; WDT: warm detection
threshold; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat pain
threshold; MDT: mechanical detection threshold; MPT: mechanical pain threshold;
WUR: wind-up ratio; VDT: vibration detection threshold; PPT: pressure pain threshold.
*p < 0.05; **p < 0.01 for iRBD patients vs. healthy control subjects. Group comparisons
were performed using two-sample t-test.
A.V. Strobel et al. / Sleep Medicine 42 (2018) 83e8986controls (lower thresholds), whereas z-scores below zero indicate
hypofunction (loss of function) and thereby lower sensitivity of the
subjects comparedwith reference controls (higher thresholds) [25].
3. Results
3.1. Patients and controls
Thirteen patients (11 males, 2 females, mean age 65.2 years)
with a clinical diagnosis of iRBD were included. In one patient,
polysomnography had been performed without video. Fifteen
healthy control subjects (12 males, 3 females, mean age 65.8 years)
were included. None of the subjects showed signs of cognitive
impairment using MMSE (cut-off score: <25 points). Demographic
data did not differ signiﬁcantly between the two groups (Table 1).
Four patients (two: unknown reasons; two: physical overload)
and three controls (two: unknown reasons; one: physical overload)
had experienced pain in the past 24 h. In this period, one subject
from each group had taken mild analgesics (ibuprofen).
Six patients were treatedwithmelatonin, and two patients were
taking clonazepam. None of the patients received dopaminergic
drugs, except for one patient who took a dopamine agonist for
restless legs syndrome. Two of the iRBD patients were treated with
selective serotonin reuptake inhibitors.
3.2. Clinical assessments and questionnaires
There was no signiﬁcant difference in height between the two
groups, although the iRBD patients weighed signiﬁcantly more
than the control subjects (Table 1).
Patients with iRBD had a higher UPDRS-III score compared with
controls (Table 1). Patients scored lower than controls in the Snifﬁn’
Sticks odour identiﬁcation test (Table 1).
Sleep quality the precedingmonth (PSQI, Table 1) and subjective
level of sleepiness (KSS, Table 1) did not differ signiﬁcantly between
iRBD patients and controls. There was no signiﬁcant difference in
the MDI score between the two groups (Table 1).
3.3. Quantitative sensory testing
Patients with iRBD had a signiﬁcantly higher CDT and TSL on the
dorsum of the hand compared with healthy controls (CDT
p ¼ 0.020, TSL p ¼ 0.001, Fig. 1). 31% of the iRBD patients and none
of the controls had abnormal low sensitivity to cold detection aboveTable 1
Demographic data and clinical characteristics.
Patients (n ¼ 13)
Sex (males/females) 11/2
Mean ± standard deviation
Age (years) 65.2 ± 7.6 (range: 54e77)
Height (cm) 179.2 ± 8.1
Weight (kg) 84.6 ± 14.4
PSQI score 6.2 ± 4.2
KSS score 3.0 ± 1.8
MMSE score 28.5 ± 1.5
SIT-12 score 5.9 ± 3.1
Median (minimumemaximum)
UPDRS-III score 3 (1e14)
MDI score 4 (0e27)
Demographic and clinical characteristics in patients with idiopathic REM sleep behavi
PSQI: Pittsburgh Sleep Quality Index; KKS: Karolinska Sleepiness Scale; MMSE: Mini-Me
motor part of the Uniﬁed Parkinson's Disease Rating Scale; MDI: Major Depression Inv
a Fisher's exact test.
b Two-sample t-test.
c ManneWhitney U test.the dorsal hand (p ¼ 0.035). Abnormal low sensitivity to detection
of temperature differences (thermal sensory limen (TSL)) above the
hand was signiﬁcantly more frequent in the patient group (62%)
than in the control group (13%, p ¼ 0.016). There was a tendency
towards a higher CDT on the dorsum of the foot in the patients in
comparison with the controls (p ¼ 0.094, Fig. 2). CPT and HPT both
on the hand and foot did not differ signiﬁcantly between the two
groups (Figs. 1 and 2). The reaction time was not signiﬁcantly
different in the patient group (250 ms ± 90 ms) compared with the
control group (230 ms ± 60 ms (mean ± standard deviation),
p ¼ 0.31).
3.4. Laser evoked potentials
The amplitude of the N2/P2 complex tended to be smaller in
the patients with iRBD (13.7 ± 12.8 mV) than in healthy controls
(33.4 ± 18.6 mV (median ± interquartile range), p¼ 0.053, Fig. 3). N2
and P2 latencies did not signiﬁcantly differ between the two groupsControls (n ¼ 15) p value
12/3 1.0a
65.8 ± 7.3 (range: 52e75) 0.84b
176.5 ± 9.0 0.42b
72.7 ± 10.9 0.020b
4.9 ± 2.1 0.33b
2.0 ± 1.0 0.096b
29.3 ± 1.4 0.15b
10.5 ± 1.4 <0.001b
1 (0e4) 0.002c
3 (0e12) 0.52c
our disorder and healthy control subjects.
ntal State Examination; SIT-12: Snifﬁn’ Sticks 12-identiﬁcation test; UPDRS-III: The
entory.
Fig. 2. Somatosensory proﬁles of the dorsal foot based on quantitative sensory testing
(QST) in patients with idiopathic REM sleep behaviour disorder and healthy control
subjects. Mean z-scores ± standard error of the mean. For further explanation, see the
Statistical analysis section. CDT: cold detection threshold; WDT: warm detection
threshold; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat pain
threshold; VDT: vibration detection threshold.
Fig. 3. Box plot showing amplitude of the N2/P2 complex in controls (n ¼ 15) and
patients (n ¼ 13). The box plot displays the median, quartiles, interquartile range (the
span of the box), and smallest and largest values in the data. “Extreme” values are
plotted as isolated dots (lying farther from the box edge than 1.5 times the inter-
quartile range).
Table 2
Results of the conditioned pain modulation (CPM) in patients and healthy controls.
Patients (n ¼ 12) Controls (n ¼ 15) p value
Absolute values (mean ± SD)
CPM response HPT (C)a 2.1 ± 2.3 1.6 ± 2.8 0.62
CPM response PPT (kPa)b 147.8 ± 68.9 60.3 ± 106.7 0.021
Percent change
CPM response HPT (%) 5.0 ± 5.7 3.6 ± 6.8 0.58
CPM response PPT (%) 44.3 ± 28.2 14.0 ± 24.0 0.006
CPM: conditioned pain modulation; HPT: heat pain threshold; PPT: pressure pain
threshold.
The calculation of the CPM response was conducted by subtracting the second test
stimuli PPT and HPT from the ﬁrst test stimuli PPT and HPT, thus the pain inhibition
was denoted with a negative value.
Group comparisons were performed using two-sample t-test.
a (mean of three HPT measurements before ice water)e(HPT measured
one minute after ice water).
b (mean of three PPT measurements before ice water)e(PPT measured immedi-
ately after ice water).
A.V. Strobel et al. / Sleep Medicine 42 (2018) 83e89 87(N2 latency: Patients 218 ± 27 ms; Controls 229 ± 29 ms
(median ± interquartile range), p ¼ 0.39. P2 latency: Patients
324 ± 65 ms; Controls 343 ± 28 ms (median ± interquartile range),
p ¼ 0.73).
3.5. Conditioned pain modulation testing
One patient did not undergo the CPM testing because of un-
stable angina. The CPM response regarding heat pain did not
signiﬁcantly differ between patients and controls (Table 2),
whereas the pain inhibition response regarding pressure pain was
larger in the patient group than the control group (Table 2).
The pain ratings during the hand in ice water immersion were
the same in the two groups (Maximum pain intensity (NRS0e10):
Patients 7.4 ± 2.0; Controls 7.7 ± 1.8 (mean ± standard deviation),
p ¼ 0.67. Maximum pain unpleasantness (NRS0-10): Patients
6.9 ± 1.4; Controls 7.3 ± 2.0 (mean ± standard deviation),
p ¼ 0.54).4. Discussion
This study found impaired somatosensory function in iRBD
patients in comparison with healthy controls, with increased
thermal detection thresholds and a tendency towards lower LEPs
amplitudes in iRBD.
These results are in accordance with former studies in PD pa-
tients, showing higher CDT andWDT in PD patients than in healthy
controls [15,16]. This indicates that impaired thermal sensory
function may occur early in the course of PD. The reduced ability to
sense cold and warm stimuli in iRBD and PD may either be caused
by changes in the central or in the peripheral nervous system.
Alpha-synuclein aggregates have been detected in multipolar
lamina I projection neurons in PD patients [26] and might be the
cause for an impaired thermal detection in our patients, as the
primary afferent thermal Ad and C ﬁbres synapse almost exclusively
with multipolar projection neurons of lamina I.
Conversely, impaired thermal sensation may be due to
dysfunction of peripheral small nerve ﬁbres. Thus, cold detection is
conveyed by thinly myelinated Ad ﬁbres, warm detection by un-
myelinated C ﬁbres, whereas TSL measures the function of both Ad
and C ﬁbres. A recent study found a reduced intraepidermal nerve
ﬁbre density (IENFD) in skin biopsies of iRBD patients compared
with healthy controls. 39% of the patients and 4.5% of the controls
had small ﬁbre neuropathy (SFN) [27]. SFN and decreased IENFD
have also been shown in PD patients [16,28]. These ﬁndings suggest
that SFN is an early feature in the neurodegenerative process and
might be used as a prodromal biomarker for PD. Studies have
demonstrated that IENFD is negatively correlated with CDT and
WDT [29e31], and therefore the increased thermal detection
thresholds found in our iRBD patients may reﬂect the affection of
the small ﬁbres. Furthermore, two recent studies demonstrated
phosphorylated alpha-synuclein deposits in dermal nerve ﬁbres
including somatosensory ﬁbres of patients with RBD [32,33]. No
deposits were found in healthy controls. This provides evidence
that somatosensory nerve ﬁbres are involved at preclinical stages of
PD and supports our ﬁndings of an impaired somatosensory func-
tion in iRBD patients. However, the association between functional
and structural small ﬁbre affection in iRBD needs to be further
investigated because QST and skin biopsy methods may comple-
ment each other in the diagnosis of SFN [34].
Our study found a tendency towards lower N2/P2 amplitudes in
iRBD patients than in controls. This is in accordance with a study
that demonstrated smaller N2/P2 amplitudes in PD patients in
comparisonwith controls [19]. These ﬁndings suggest an abnormal
processing of the nociceptive laser input in both PD and iRBD
A.V. Strobel et al. / Sleep Medicine 42 (2018) 83e8988patients. This dysfunction may be located in the central nervous
system or in the small peripheral nerve ﬁbres, as LEPs is conveyed
by thinly myelinated Ad ﬁbres. A previous study found a positive
correlation between N2/P2 amplitude and IENFD and that patients
with SFN had lower N2/P2 amplitude than healthy control subjects
[35], suggesting that the lower N2/P2 amplitude in iRBD patients
might be due to SFN.
Conﬂicting ﬁndings regarding CPT and HPT in PD have been
published [15e17], which might reﬂect the unaltered thermal pain
thresholds in PD patients. In our study we found no difference of
the CPT and HPT between the iRBD patient and control group,
suggesting that cold and heat pain perception are not altered in
iRBD patients.
Patients with iRBD did not show decreased function of the
descending pain inhibitory system using CPM testing e in fact, pa-
tients had a larger inhibition of PPT than controls, which is difﬁcult to
explain and may be a coincidental ﬁnding. A previous study has
demonstrated that CPM responses did not differ between PDpatients
and healthy controls using a paradigm consisting of heat pain as the
test stimulus and a cold pressor task as the conditioning stimulus
[21]. Hence, theseﬁndings suggest that neither PDnor iRBD is related
to general deﬁcits of the descending pain inhibitory system.
It is unclear if these ﬁndings have clinical implications for in-
dividual patients. SFN may lead to neuropathic pain, yet, in this
study, iRBD patients and healthy controls did not differ regarding
clinical pain symptoms. However, the question if iRBD patients
might suffer from more pain than the general population was not
the aim of this study, and a bigger study group would be needed to
answer this question.
A limitation of this study is the small sample size, and a larger
sample of iRBD patients is necessary to conﬁrm our results. Labo-
ratory tests of vitamin B12, folic acid, and glucose were not per-
formed in all patients. Consequently, metabolic causes of a subtle
neuropathy might have been undetected. Electromyography (EMG)
was not performed to rule out a potential SFN. Comorbidity,
especially cardiovascular disease and obstructive sleep apnoea, was
more frequent in iRBD patients than controls. UPDRS scores were
higher in iRBD patients than controls, indicating a slightly higher
motor impairment in this group. However, none of the patients
fulﬁlled diagnostic criteria for PD [36]. We did not correct for
multiple testing, and some of the signiﬁcant results could therefore
have been found by coincidence alone. Strength of this study is that
the gender and age distribution was very similar among the pa-
tients and controls. Furthermore, we used a standardised QST
protocol and transformed the QST data into z-values based on a
normative reference database of healthy controls, so it is reasonable
to compare our results with other standardised QST studies. The
neurophysiologists, who placed the measurement cursors on the
LEPs curves, were blinded regarding if the subject was a patient or
control. As somatosensory function and pain perception in iRBD
have not been investigated before, this study provides new insight
into sensory processing in the early stage of synucleinopathy.
Future studies should address the predictive value of QST and
LEPs measures in iRBD patients regarding time to disease conver-
sion and type of evolving neurodegenerative alpha-synucleinopathy.
Such studies could clarify if impaired somatosensory function might
be used as a prodromal diagnostic biomarker for neurodegenerative
disease. In addition, thermal detection thresholds and LEPs should be
investigated together with IENFD in a larger sample of iRBD patients.
5. Conclusion
This study found thermal sensory impairment and reduced N2/P2
amplitude in patients with iRBD in comparison with controls, which
might be due to functional affection of the small nerve ﬁbres. Furtherstudies are required to assess if impaired somatosensory function can
be used as a marker for incipient alpha-synucleinopathy-mediated
neurodegeneration.
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